An officer proposes selling Kiniksa (KNSA) shares, including 97,572 from an option exercise.

Kiniksa Pharmaceuticals International, plc officer Ross Moat has proposed selling 103,585 Class A ordinary shares, valued at approximately $9.75 million, through Charles Schwab & Co., Inc. The proposed sale, with an approximate date of October 30, 2026, includes shares from two restricted stock lapses and a significant portion (97,572 shares) from an employee stock option exercise. This Form 144 filing provides details on the origin of the shares and the regulatory context of the sale.